In the first post of this series, I described what happens to the human body at ground zero of a 10 to 15-kiloton nuclear detonation: the zone within 800 meters of the hypocenter. There, the thermal ...

Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also ...

Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of ...

The MarketWatch News Department was not involved in the creation of this content. -- Primary endpoint of QUILT-3.078 is overall survival; median overall survival has not yet been reached, with 19 of ...

QUILT-3.078 enrolled patients with recurrent GBM at first recurrence. In the spIND population, seven patients were first line and are alive to date. Randomized clinical trials for both first line and ...

As of January 22, 2026, the study has enrolled 23 patients with recurrent or progressive GBM who progressed following standard-of-care therapy, including surgery, radiation, and temozolomide-based ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...

Measuring the lymphocytes — white blood cells that fight infection — in a patient’s blood can be used to predict outcomes in non-Hodgkin lymphoma patients who receive CAR T-cell therapy, according to ...

Monitoring ALC in the first 14 days post-cilta cel infusion may help identify patients with RRMM who are at high risk of developing neurocognitive TEAEs and cranial nerve palsy. Measuring certain ...

Neutrophils and lymphocytes are crucial players in cancer progression, with the neutrophil-to-lymphocyte ratio (NLR) emerging as a potential prognostic biomarker. However, its clinical relevance ...